A novel signature of disulfidptosis-related lncRNAs predicts prognosis in glioma: Evidence from bioinformatic analysis and experiments
Authors:
Preprint
- 18 November 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
Background: Glioma is the most common primary malignant brain tumor, with a high mortality and morbidity rate. Disulfidptosis is a recently discovered new regulatory cell death. This study established a prognostic signature through disulfidptosis related lncRNA (DRL), and identified new prognostic biomarkers for glioma.Methods: RNA-seq and clinical data of glioma patients were obtained from The Cancer Genome Atlas database. 24 Disulfidptosis-related genes were obtained from previous studies. Prognosis-related DRLs were identified and used to establish the model. The predictive efficacy of the model was evaluated using Kaplan-Meier survival analysis, receiver operating characteristic curves, and concordance index. Differential gene expression analysis, functional enrichment analysis, and immune-related analysis were performed to compare the differences between samples with different risk scores. Finally, the biological function of LINC02542 was validated in glioma cell lines (U251 and U87).Results We successfully developed and validated a glioma prognosis model that includes 7 DRLs. This model stratified glioma patients into low-risk and high-risk groups, with the low-risk group exhibiting significantly longer overall survival (OS). Functional enrichment analysis and immune-related analysis identified differences in immune pathways, immune cell infiltration, and immune checkpoint characteristics between the two risk groups. Drug sensitivity analysis identified several chemotherapy drugs and targeted inhibitors that are more sensitive in the high-risk population. Finally, in vitro experiments confirmed that knocking down LINC02542 can inhibit the proliferation, migration, and invasion of glioma cells.Conclusion An effective glioma prognostic model including 7 DRLs was established. LINC02542 was identified as a prospective biomarker and potential therapeutic target for gliomaKeywords
All Related Versions
This publication has 60 references indexed in Scilit:
- Comprehensive characterization of cell disulfidptosis in human cancers: An integrated pan-cancer analysisGenes & Diseases, 2024
- CTLA-4 blockade induces a microglia-Th1 cell partnership that stimulates microglia phagocytosis and anti-tumor function in glioblastomaImmunity, 2023
- Malignant Glioma2023
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent GlioblastomaJAMA Oncology, 2020
- Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null GliomaCancer Cell, 2019
- Gemcitabine and glioblastoma: challenges and current perspectivesDrug Discovery Today, 2018
- Anti-GITR therapy promotes immunity against malignant glioma in a murine modelCancer Immunology, Immunotherapy, 2016
- Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cellsCancer Immunology, Immunotherapy, 2016
- ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosisActa Neuropathologica, 2013
- Selection of reference genes for use in quantitative reverse transcription PCR assays when using interferons in U87MGMolecular Biology Reports, 2012